|
1
|
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
|
J Clin Invest
|
2008
|
4.95
|
|
2
|
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models.
|
Cancer Cell
|
2012
|
3.39
|
|
3
|
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.
|
Cancer Res
|
2010
|
2.14
|
|
4
|
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.
|
Sci Transl Med
|
2013
|
1.67
|
|
5
|
PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.
|
Proc Natl Acad Sci U S A
|
2013
|
1.57
|
|
6
|
Activation of PI3K signaling in Merkel cell carcinoma.
|
Clin Cancer Res
|
2012
|
1.45
|
|
7
|
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.
|
Clin Cancer Res
|
2013
|
1.21
|
|
8
|
Differences underlying EGFR and HER2 oncogene addiction.
|
Cell Cycle
|
2010
|
1.02
|
|
9
|
Thematic review series: sphingolipids. Ganglioside GM3 suppresses the proangiogenic effects of vascular endothelial growth factor and ganglioside GD1a.
|
J Lipid Res
|
2008
|
0.92
|
|
10
|
Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers.
|
Cancer Sci
|
2014
|
0.82
|
|
11
|
Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutations.
|
J Thorac Oncol
|
2015
|
0.77
|
|
12
|
Cyclins D3 and E go hand in hand with Cdk4/6 in diffuse large B-cell lymphoma.
|
Cell Cycle
|
2010
|
0.75
|